Matthew Taylor MD, Ph.D.

Director, Adult Clinical Genetics, Department of Medicine and Associate Director of Personalized Medicine, Colorado Center for Personalized Medicine, University of Colorado Denver Anschutz Medical Campus

Clinically, he directs the Adult Medical Genetics clinic that serves adults and families with genetic conditions in the Denver and Rocky Mountain region.  The clinic services include genetic diagnosis, testing, and counseling.  Additionally, the clinic serves as a regional hub for recruitment of patients with rare genetic diseases as well as for clinical trials in genetic diseases where novel therapies are now coming online in the trial arena.

Many of his research subjects are initially identified through this clinic and feed into his laboratory’s research on inherited cardiomyopathies, major causes of heart failure and heart transplantation.  The current work involves whole Exome studies in multi-generational cardiomyopathy families. This work has been funded through the NIH and most recently the laboratory was informed of successful funding from the Leducq Foundation as part of a multi-center trans-Atlantic partnership to study mechanisms of arrhythmias in cardiomyopathies.  In addition to descriptive and mechanistic studies in cardiomyopathies, his group is just initiating two clinical trials in rare forms of hereditary cardiomyopathy where specific mutational sub-classes of disease are targeted with therapies designed to benefit those individuals with mutations in key subsets of cardiomyopathy genes.

Beyond cardiomyopathies, Dr. Taylor is involved in therapeutic studies in rare inborn errors of metabolism including past and ongoing treatment trials in Gaucher, Fabry, and Pompe diseases.  The rapid advances from genetic discovery to and understanding of pathophysiology to treatment development ensures that additional studies in rare genetic conditions will shortly be arriving on the scene.

In the area of medical and scientific education, Dr. Taylor co-directs the year I Molecules to Medicine Block in the Medical school, is associate track director in the Clinical Science PhD Program, and is co-director of the BA/BS-MD Pipeline program.

 

Michael G. Kahn MD, Ph.D.

Professor of Pediatrics at the University of Colorado Denver; Biomedical Informatics Core Director of the Colorado Clinical and Translational Sciences Institute (CCTSI); co-Director of the Colorado Center for Personalized Medicine; and Director of Research Informatics at Children’s Hospital Colorado.

Dr. Kahn is responsible for a campus-wide clinical and research data warehouse that combines data from four clinical, financial and research institutions. Dr. Kahn is the informatics lead for PEDSnet and PORTAL, two PCORI national clinical data research networks. His informatics research focus area is developing measures of data quality in distributed research networks.

 

Christina Aquilante, Pharm.D.

Associate Professor, Skaggs School of Pharmacy, University of Colorado Anschutz Medical Campus

Dr. Aquilante’s patient-oriented clinical research program is focused on pharmacogenomics in patients with cardiovascular and metabolic diseases.  Her current work is aimed at genetic predictors of drug disposition (pharmacokinetics), response (pharmacodynamics) and adverse effects in heart transplant recipients.  Her research program also includes a “multi-omics” component, which is being used to elucidate mechanisms underlying left ventricular assist device (LVAD)-related adverse effects in patients with advanced heart failure.

 

Andrew A. Monte, M.D.

Associate Professor Emergency Medicine & Medical Toxicology Departments of Emergency Medicine & Pharmaceutical Sciences, University of Colorado Denver-Anschutz Medical Center Aurora, CO & Rocky Mountain Poison & Drug Center, Denver Health & Hospital Authority, Denver, CO

Dr. Monte’s primary research interest is in personalized medicine. He focuses on predicting medication efficacy and safety using genomic and metabolomic techniques. Dr. Monte’s toxicology research focuses on epidemiology and ethnography of novel drugs of abuse, opioid toxicity, and marijuana use.

 

Ivana V. Yang, Ph.D.

Associate Professor, University of Colorado Denver

The focus of Dr. Yang’s research has largely been on epigenetic regulation and transcriptional profiles in pulmonary fibrosis, asthma, and innate immunity. In this work, she has identified molecular subtypes of pulmonary fibrosis, gene expression profiles of environmental exposures in asthma, and DNA methylation changes associated with the development of asthma and pulmonary fibrosis. Dr. Yang has recently expanded her research program to encompass studying epigenetic regulation of gene expression in other diseases and exposures, including regulation of immune response in granulomatous lung disease as well as the role of epigenetics in metabolic disorders.

 

Michelle Daya, Ph.D.

Research Instructor, Biomedical Informatics & Personalized Medicine, University of Colorado Anschutz Medical Campus

Dr. Daya’s research interests include the statistical analysis of genetic data to better understand disease and improve health outcomes. Currently, her research is focused on identifying and understanding genetic risk factors of asthma, particularly in populations of African ancestry.

 

Catherine Lozupone, Ph.D.

Assistant Professor, Division of Biomedical Informatics and Personalized Medicine, Department of Medicine, Anschutz Medical Campus

The main focus of Dr. Lozupone’s research is to understand factors that shape human microbiota composition in health and disease and to elucidate the functional consequences of compositional differences, both in terms of the biological/metabolic properties of individual bacteria and host interactions. Her work has included the development of algorithms and tools for the analysis of microbial communities based on sequence information.  Her lab is currently working to understand a potential role for the human micro biome in the pathology of a variety of diseases, including HIV/AIDS, asthma, autism, and Graft Versus Host Disease (GVHD). Important to these projects are techniques for integrating various ‘omic datasets, most notably metagenomic, transcriptomic and metabolomics datasets. Another goal in her lab is to use bacterial genome sequences to predict and test biological properties of key bacteria that associate with disease, such as prediction of immune modulatory molecular factors that may drive inflammatory phenotypes in the gut.

 

Katerina Kechris, Ph.D.

Associate Professor and Graduate Program Co-Director in the Department of Biostatistics and Informatics, Colorado Center for Personalized Medicine, University of Colorado Denver Anschutz Medical Campus

Dr. Kechris completed her PhD in Statistics at the University of California Berkeley in 2003. She then spent two years at the University of California San Francisco as a post-doctoral fellow in Computational Biology before joining the faculty at the University of Colorado Anschutz Medical Campus.

Her research interests are the development and application of statistical and computational methods for analyzing high throughput data. She has several focus areas: (1) analyzing transcription factor binding and miRNA data to study the regulation of transcription and post-transcriptional processing, (2) examining the genetic and epigenetic factors controlling gene expression, and (3) the integration of different omics data. Dr. Kechris collaborates with investigators using ‘omics technologies to study alcohol abuse, chronic obstructive pulmonary disease and childhood diabetes.